It has come to the attention of the members of the Canadian Headache Society that some insurance companies are refusing to cover the combination of Botox and a CGRP monoclonal antibody (BTX + CGRP MAB). Currently available CGRP monoclonal antibodies are erenumab (Aimovig) and
galcanezumab (Emgality), Fremanezumab (Ajovy) and eptinezumab (Viyepti). All CGRP antibodies have shown effectiveness and safety in robust randomized-controlled trials (1).
Insurance coverage of BOTOX and CGRP
